Abstract:Malignant gliomas are the most common (60–70%) of all CNS/brain tumors. Annually, thereare approximately five cases of malignant gliomas per 100,000 people, and over 14,000 newcases are diagnosed each year in the United States (1,2). Surgery remains the standard therapyfor primary brain tumors. Although surgery may be combined with radiation therapy and/orfollowed with chemotherapy to destroy remaining cancer cells, patients still have a poorsurvival (3-5). In recent years, Temozolomide (TMZ, Temodar®), a prodrug which undergoesspontaneous conversion to the active alkylating agent (Charts 1 and 2) has emerged as a potentchemotherapeutic agent (6). In combination with radiotherapy, it has been shown tosubstantially increase median survival compared with radiotherapy alone (7). However, TMZhas considerable toxicity, which prevents therapeutic dosage increase. Moreover, anotherlimiting factor of TMZ treatment is tumor resistance to the drug (8-10).Recently, efforts have been made to develop delivery systems for conventionalchemotherapeutic drugs. Polymer-based delivery systems are less immunogenic than proteinbased,e.g. viral vectors, and allow repetitive treatments without acute or chronic host immuneresponse (11-14). Compared with most chemotherapeutic molecules, macromolecules offerseveral advantages, including tumor targeting, increased solubility, enhanced accumulation insolid tumors, decreased general toxicity, increased maximum tolerated doses, circumventionof multidrug resistance and enhanced apoptosis induction (15,16). Nanodrugs can selectivelyaccumulate in tumor through a passive targeting mechanism known as enhanced permeabilityand retention (EPR) effect (17-19). Targeting efficiency is substantially enhanced bycombining nanodrugs with specific antibodies that allow targeting by binding to antigens onthe tumor cell surface (20-22).To avoid systemic side effects by orally administered TMZ, targeting to brain tumor would behighly important. Recently, Brem (23) and Akbar (24) have administered a solid mixture ofbiodegradable polymer and TMZ directly into the brain tumor in animal models. The drug wasprogressively released during degradation of the embedding polymer material and significantlyprolonged the survival time of experimental animals. These methods are invasive, and the drugis applied at the time of surgery. Moreover, gliomas are tumors with the ability to developrecurrences; thus, systemic and targeted delivery of TMZ would be a more beneficial treatmentapproach.Following I.V. administration, we have delivered antisense oligonucleotides specifically tobrain tumor using the targeted nanoconjugate delivery system, Polycefin (21). Thenanoconjugate platform, poly(β-L-malic acid) (PMLA), is biodegradable, non-toxic and nonimmunogenic,containing numerous pendant carboxyl groups suitable for the covalentattachment of prodrugs and other useful molecules. For the delivery into the cytoplasm ofrecipient glioma cells, we conjugated TMZ in its hydrazide form with PMLA along with antitransferrinreceptor (TfR) monoclonal antibody (mAb) for tumor targeting by receptormediatedendocytosis (21) and pH-sensitive trileucine (LLL) for disruption of endosomalmembranes.

Brain-Targeted polymersome codelivery of siRNA and temozolomide for

Brain-targeted polymersome codelivery of siRNA and temozolomide for effective glioblastoma chemo-RNAi synergistic therapy

Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood–Brain Barrier Opening

Nano-Codelivery of Temozolomide and siPD-L1 to Reprogram the Drug-Resistant and Immunosuppressive Microenvironment in Orthotopic Glioblastoma

Intelligent Nanoparticles With pH-Sensitive Co-Delivery of Temozolomide and siEGFR to Ameliorate Glioma Therapy

Angiopep-2 Modified Cationic Lipid-Poly-Lactic-Co-Glycolic Acid Delivery Temozolomide and DNA Repair Inhibitor Dbait to Achieve Synergetic Chemo-Radiotherapy Against Glioma.

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma

Codelivery of Temozolomide and Sirna with Polymeric Nanocarrier for Effective Glioma Treatment

A Biomimetic Nanomedicine Targets Orthotopic Glioblastoma by Combinatorial Co‐Delivery of Temozolomide and a Methylguanine‐DNA Methyltransferase Inhibitor

Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(β-L-malic acid)

Cation-Free siRNA Micelles as Effective Drug Delivery Platform and Potent RNAi Nanomedicines for Glioblastoma Therapy

Dual-Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy

Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy

Use of surface-modified porous silicon nanoparticles to deliver temozolomide with enhanced pharmacokinetic and therapeutic efficacy for intracranial glioblastoma in mice

Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy

Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells

Brain co‐delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy

Brain co‐delivery of first‐line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy

Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound

Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma

Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma.